NBIX Neurocrine Biosciences, Inc. - Common Stock
Neurocrine Biosciences, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
और पढ़ें
Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kyle Gano as of October 11, 2024. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).
The company is also developing treatments that are in various stages of clinical research for Parkinson's disease, Tourette syndrome, and congenital adrenal hyperplasia and with a partner for endometriosis and uterine fibroids.
History
Neurocrine was founded in San Diego, California, in 1992. The company's academic founders were Wylie Vale of the Salk Institute for Biological Studies, and Lawrence Steinman of Stanford University. The company was backed and organized by Larry Bock of Avalon Ventures among others.
In 1995, the company collaborated with Belgium-based Janssen Pharmaceutica N.V. to develop treatments for psychiatric disorders utilizing corticotropin releasing factor (CRF) antagonists, a class of compounds to treat psychiatric, neurological and gastrointestinal diseases including anxiety, depression and irritable bowel syndrome. The company underwent an IPO in May 1996, listing on the NASDAQ exchange under the symbol NBIX and raising $34.2 million.
In October 1996, Eli Lilly and Company agreed to pay Neurocrine $74 million over five years to develop drugs for obesity and Alzheimer's disease based on its research of CRF-binding protein-ligand inhibitors.
In July 2001, Neurocrine and GlaxoSmithKline entered into a worldwide research, development and commercialization agreement, including a collaborative research program for up to five years to identify and develop CRF-R antagonist compounds. The collaboration also included worldwide development and commercialization of NBI-34041 as well as potential backup candidates resulting from the research program. Neurocrine received upfront fees and early milestone payments totaling $25.5 million.
In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales goals. In May 2006, the FDA issued a non-approvable letter for a modified-release 15 mg formulation of indiplon and an approvable letter with stipulations for 5 mg and 10 mg immediate-release formulations. As a result, Pfizer terminated its agreement with Neurocrine. Following a resubmission of the 5 mg and 10 mg formulations in December 2007, Neurocrine's new drug application was deemed 'approvable' but the FDA requested additional studies. The company discontinued development of the drug in the United States. In 2007, Neurocrine partnered with Dainippon Sumitomo Pharma to develop and commercialize indiplon in Japan. The deal paid Neurocrine $20 million up front with the ability to receive milestone payments and royalties based on the commercialization of indiplon in Japan.
Kevin Gorman replaced Gary Lyons as CEO of the company in January 2008. Lyons was CEO and president of the company since its founding and maintained a role on the company's board of directors.
On June 16, 2010, Neurocrine agreed to a deal with AbbVie Inc. (previously Abbott Laboratories) worth up to $575 million with Neurocrine granting AbbVie the worldwide rights to develop and commercialize elagolix, an oral gonadotropin-releasing hormone (GnRH) antagonist to treat endometriosis and uterine fibroids. The deal paid Neurocrine $75 million up front.
In April 2017, the FDA approved valbenazine for the treatment of TD. At the time of approval, it was the first and only drug approved for adults with TD. Neurocrine is also studying valbenazine in clinical trials for the treatment of Tourette Syndrome. In October 2017, Neurocrine announced that it had been granted orphan drug designation status from the FDA for valbenazine for the treatment of pediatric patients with Tourette syndrome.
In February 2017, Neurocrine announced an exclusive licensing agreement for the development and commercialization of the Parkinson's disease drug, opicapone, in North America with the Portugal-based pharmaceutical company Bial. As part of the agreement, Neurocrine provided an upfront payment of $30 million and agreed to fund development activities for FDA approval in the United States. Bial is eligible to receive additional milestone payments of up to $115 million and a percentage of net sales.
In September 2017, AbbVie submitted a NDA to the FDA for elagolix for the management of endometriosis and associated pain. The submission was supported by two similar Phase 3 clinical studies involving 1,700 women. In October 2017, AbbVie and Neurocrine announced that the FDA granted priority review for the elagolix NDA. A final regulatory decision on the drug will come during the third quarter of 2018. The companies are also developing elagolix for the treatment of uterine fibroids which is in Phase III development.
In 2021,Nexera Pharmain Japan licensed out its investigational schizophrenia drug, NBI-1117568, to Neurocrine Biosciences for development.
In August 2024, Neurocrine announced the results of a Phase II clinical trial of NBI-1117568 . The drug demonstrated a 7.5-point improvement in the Positive and Negative Syndrome Scale (PANSS), which was lower than the 8.4-point improvement seen with KarXT (developed by Karuna Therapeutics) and the 12.7-point improvement seen with Emraclidine (developed by Cerevel Therapeutics), both of which were also in clinical trials at the time. Additionally, the study found no dose-dependent response to NBI-1117568. As a result, Neurocrine's stock price fell 19% the following day as investors were disappointed by the results.
Product pipeline
Elagolix – gonadotropin-releasing hormone receptor antagonist undergoing FDA review for the treatment of endometriosis and in clinical trials for uterine fibroids
Opicapone – A once daily catechol-O-methyl transferase inhibitor in trials for Parkinson's disease
NBI-74788 – Corticotropin-releasing factor (CRF) receptor antagonist
NBI-1117568 - A drug that stimulates muscarinic receptors and is used to treat schizophrenia.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
NBIX स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
NBIX स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
NBIX विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
- मजबूत खरीद 14 38.9%
- खरीदें 17 47.2%
- होल्ड 5 13.9%
- बेचें 0 0.0%
- मजबूत बिक्री 0 0.0%
12-महीने का मूल्य लक्ष्य
27 विश्लेषक · 2026-08-15Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
| Period | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|
| 30 जून 2026 | $1.39 | $1.37 | 0.02% |
| 31 मार्च 2026 | $1.91 | $1.20 | 0.71% |
| 31 दिसमबर 2025 | $1.91 | $1.20 | 0.71% |
| 30 सितमबर 2025 | $2.04 | $1.62 | 0.42% |
| 30 जून 2025 | $1.06 | $0.99 | 0.07% |
| 31 मार्च 2025 | $0.08 | $0.56 | -0.48% |
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| NBIX | $14.20B | 30.4 | 21.4% | 16.7% | 16.1% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
| BBIO | $14.90B | -20.2 | 126.3% | -146.0% | 41.2% | — |
| BMRN | $11.43B | 33.0 | 12.9% | 10.8% | 5.8% | — |
| EXEL | $11.44B | 15.7 | 7.0% | 33.7% | 37.3% | — |
| ARWR | $4.68B | -3449.0 | 23258.2% | -0.20% | -0.50% | — |
| MDGL | $13.30B | -45.3 | 432.1% | -30.1% | -44.4% | — |
| HALO | $7.93B | 26.3 | 37.5% | 22.7% | 166.1% | — |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण 17
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Cost of Revenue | $52M | $34M | $40M | $23M | $14M | $10M | · | $5M | $1M | $0 | $0 | · | |
| R&D Expense | · | · | · | · | · | · | · | $161M | $122M | $94M | $81M | $46M | |
| SG&A Expense | $1.16B | $1.01B | $888M | $753M | $583M | $433M | $354M | $249M | $170M | $68M | $32M | $18M | |
| Operating Expenses | $2.24B | $1.78B | $1.64B | $1.24B | $1.03B | $883M | $716M | $414M | $293M | $162M | $114M | $64M | |
| Operating Income | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | $-94M | $-64M | |
| Interest Expense | · | · | $5M | $7M | $26M | $33M | $32M | $30M | $20M | $0 | $0 | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $3M | $2M | $629.0K | |
| Other Non-op | $86M | $-84M | $81M | $-35M | $-1M | $-56M | $-26M | $-15M | $-11M | $6M | $20.0K | $18.0K | |
| Pretax Income | $705M | $486M | $332M | $214M | $101M | $107M | $46M | $22M | $-143M | $-141M | · | · | |
| Income Tax | $227M | $145M | $82M | $59M | $12M | $-301M | $10M | $700.0K | $0 | $0 | $0 | $0 | |
| Net Income | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| EPS (Basic) | $4.81 | $3.40 | $2.56 | $1.61 | $0.95 | $4.38 | $0.40 | $0.23 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| EPS (Diluted) | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 | $4.16 | $0.39 | $0.22 | $-1.62 | $-1.63 | $-1.05 | $-0.81 | |
| Shares (Basic) | 99,500,000 | 100,400,000 | 97,700,000 | 95,800,000 | 94,600,000 | 93,100,000 | 91,600,000 | 90,200,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| Shares (Diluted) | 102,500,000 | 103,700,000 | 101,000,000 | 98,900,000 | 97,900,000 | 97,800,000 | 95,700,000 | 95,400,000 | 88,089,000 | 86,713,000 | 84,496,000 | 74,577,000 | |
| EBITDA | $619M | $570M | $251M | $249M | $102M | $163M | $72M | $37M | $-131M | $-147M | · | $-64M |
बैलेंस शीट 28
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $713M | $233M | $251M | $263M | $341M | $187M | $112M | $142M | $255M | $83M | $74M | $31M | |
| Short-term Investments | · | · | · | · | $370M | $614M | $558M | $509M | $261M | $224M | $305M | $163M | |
| Receivables | $687M | $479M | $439M | $350M | $186M | $157M | $127M | $57M | $31M | $0 | · | · | |
| Inventory | $69M | $57M | $38M | $35M | $30M | $28M | $17M | $11M | $1M | $0 | · | · | |
| Prepaid Expense | $171M | $48M | · | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $116M | $64M | $98M | $79M | $46M | $30M | $17M | $19M | $7M | $3M | $5M | $4M | |
| Current Assets | $2.52B | $1.72B | $1.61B | $1.45B | $973M | $1.02B | $831M | $738M | $555M | $310M | $384M | $198M | |
| PP&E (Net) | $90M | $83M | $71M | $59M | $59M | $45M | $42M | $34M | $11M | $6M | $3M | $3M | |
| PP&E (Gross) | $208M | $189M | $154M | $125M | $110M | $86M | $76M | $62M | $38M | $32M | $30M | $31M | |
| Accum. Depreciation | $118M | $106M | $83M | $66M | $52M | $42M | $34M | $28M | $28M | $26M | $27M | $29M | |
| Goodwill | $6M | $6M | $6M | $5M | $0 | · | · | · | · | · | · | · | |
| Intangibles | $5M | $36M | $36M | $37M | $0 | · | · | · | · | · | · | · | |
| Other Non-current Assets | $49M | $52M | $50M | $25M | $4M | $6M | $0 | · | · | · | · | · | |
| Total Assets | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Accounts Payable | $674M | $462M | $449M | $348M | $226M | $169M | $141M | $86M | $6M | $5M | $3M | $246.0K | |
| Accrued Liabilities | · | · | · | · | · | · | · | · | · | $21M | $19M | $12M | |
| Current Liabilities | $743M | $508M | $655M | $538M | $246M | $186M | $565M | $88M | $54M | $30M | $26M | $16M | |
| Capital Leases | $415M | $455M | $258M | $94M | $105M | $94M | $87M | $0 | · | · | · | · | |
| Deferred Tax | $0 | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $220M | $166M | $106M | $30M | $12M | $10M | $17M | $36M | $0 | $113.0K | $221.0K | $260.0K | |
| Total Liabilities | $1.38B | $1.13B | $1.02B | $661M | $698M | $608M | $669M | $512M | $445M | $50M | $50M | $34M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $91.0K | $89.0K | $87.0K | $86.0K | $76.0K | |
| Paid-in Capital | · | · | · | · | · | · | · | · | · | · | · | $1.04B | |
| Retained Earnings | $448M | $29M | $-157M | $-407M | $-636M | $-725M | $-1.13B | $-1.18B | $-1.20B | $-1.06B | $-915M | $-826M | |
| AOCI | $13M | $6M | $7M | $-8M | $-2M | $2M | $1M | $-2M | $-2M | $-318.0K | $-977.0K | $-277.0K | |
| Stockholders' Equity | $3.25B | $2.59B | $2.23B | $1.71B | $1.37B | $1.13B | $637M | $481M | $372M | $315M | $424M | $209M | |
| Liabilities + Equity | $4.63B | $3.72B | $3.25B | $2.37B | $2.07B | $1.73B | $1.31B | $993M | $818M | $365M | $475M | $243M | |
| Shares Outstanding | 100,100,000 | 99,400,000 | 98,700,000 | 96,500,000 | 94,900,000 | 93,500,000 | 92,300,000 | 90,797,000 | 88,793,903 | 86,883,300 | 86,262,594 | 76,465,942 |
नकदी प्रवाह 15
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | · | · | · | · | · | $4M | $2M | $1M | $1M | $827.0K | |
| Stock-based Comp | $218M | $196M | $194M | $173M | $134M | $100M | $75M | $58M | $43M | $28M | $28M | $10M | |
| Deferred Tax | $164M | $-123M | $-61M | $22M | $6M | $-311M | $0 | $0 | · | · | · | · | |
| Amort. of Intangibles | $4M | $4M | $4M | $500.0K | $0 | $0 | · | · | · | · | · | · | |
| Operating Cash Flow | $783M | $595M | $390M | $339M | $256M | $228M | $147M | $101M | $-94M | $-106M | $-38M | $-47M | |
| CapEx | $34M | $38M | $28M | $16M | $23M | $11M | $15M | $25M | $7M | $4M | $2M | $2M | |
| Investing Cash Flow | $-264M | $-127M | $-467M | $-177M | $-130M | $4M | $-211M | $-243M | $-251M | $113M | · | · | |
| Stock Issued | $129M | $122M | $65M | $45M | $28M | $29M | $32M | $30M | $14M | $2M | $277M | $139M | |
| Stock Repurchased | $168M | $300M | $0 | $0 | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-38M | $-178M | $65M | $45M | $28M | $29M | $27M | $30M | $14M | $2M | · | $139M | |
| Financing Cash Flow | $-38M | $-487M | $65M | $-234M | $27M | $-158M | $32M | $30M | $517M | $2M | · | · | |
| Net Change in Cash | $480M | $-18M | $-12M | $-73M | $154M | $75M | $-32M | $-112M | $171M | $9M | $43M | $-14M | |
| Taxes Paid | $81M | · | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $749M | $557M | $362M | $323M | $233M | $218M | $137M | $77M | $-101M | $-110M | · | $-49M | |
| Levered FCF | · | · | $358M | $318M | $210M | $92M | $112M | $47M | · | · | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| Net Margin | 16.7% | 14.5% | 13.2% | 10.4% | 7.9% | 38.9% | 4.7% | 4.7% | -88.2% | -940.6% | · | · | |
| Pretax Margin | 24.7% | 20.6% | 17.6% | 14.4% | 8.9% | 10.2% | 5.9% | 4.8% | · | · | · | · | |
| EBITDA Margin | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% | 15.6% | 9.2% | 8.2% | -81.3% | -982.5% | · | · | |
| ROA | 11.5% | 9.8% | 8.9% | 7.0% | 4.7% | 26.8% | 3.2% | 2.3% | -24.1% | -33.6% | · | -30.4% | |
| ROE | 16.1% | 12.9% | 11.8% | 9.5% | 6.6% | 42.2% | 6.1% | 4.5% | -41.5% | -38.2% | · | -36.8% | |
| ROIC | 12.9% | 15.5% | 8.5% | 10.5% | 6.6% | 55.2% | 9.0% | 7.4% | · | · | · | · |
तरलता और शोधन क्षमता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 | 5.4 | 1.5 | 8.4 | 10.2 | 10.2 | · | 12.7 | |
| Quick Ratio | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 | 5.1 | 1.4 | 2.2 | 10.1 | 10.1 | · | 12.4 | |
| Interest Coverage | · | · | 54.5 | 35.1 | 4.0 | 5.0 | 2.3 | 1.2 | -6.7 | · | · | · |
दक्षता 3
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | 0.7 | 0.7 | 0.5 | 0.3 | 0.0 | · | 0.0 | |
| Inventory Turnover | 0.8 | 0.7 | 1.1 | 0.7 | · | · | · | 0.8 | · | · | · | · | |
| Receivables Turnover | 4.9 | 5.1 | 4.8 | 5.6 | 6.6 | 7.4 | 8.6 | 10.3 | 10.4 | · | · | · |
विकास दरें 9
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 21.4% | 24.8% | 26.8% | 31.3% | 8.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 24.3% | 27.6% | 21.7% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 22.3% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 41.9% | 33.2% | 58.3% | 69.6% | -77.9% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | 44.1% | 52.9% | -16.0% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 2.3% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 40.2% | 36.7% | 61.6% | 72.4% | -78.0% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | 45.8% | 56.2% | -15.0% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 3.3% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B | $1.05B | $788M | $451M | $162M | $15M | $20M | $0 | |
| Net Income TTM | $479M | $341M | $250M | $154M | $90M | $407M | $37M | $21M | $-143M | $-141M | $-89M | $-61M | |
| Market Cap | $14.20B | $13.57B | $13.00B | $11.53B | $8.08B | $8.96B | $9.92B | $6.48B | $6.89B | $3.36B | · | $1.71B | |
| P/E | 30.4 | 41.5 | 53.3 | 76.6 | 92.6 | 23.0 | 275.6 | 324.6 | -47.9 | -23.7 | -53.9 | -27.6 | |
| P/S | 5.0 | 5.8 | 6.9 | 7.7 | 7.1 | 8.6 | 12.6 | 14.4 | 42.6 | 224.2 | · | · | |
| P/B | 4.4 | 5.2 | 5.8 | 6.7 | 5.9 | 8.0 | 15.6 | 13.5 | 18.5 | 10.7 | · | 8.2 | |
| P / Tangible Book | 4.4 | 5.3 | 5.9 | 6.9 | 5.9 | 8.0 | · | · | · | · | · | · | |
| P / Cash Flow | 18.1 | 22.8 | 33.4 | 34.0 | 31.5 | 39.2 | 65.2 | 64.0 | -73.0 | -31.7 | · | -36.2 | |
| P / FCF | 19.0 | 24.4 | 36.0 | 35.7 | 34.7 | 41.2 | 72.2 | 84.7 | -68.0 | -30.5 | · | -35.0 | |
| Earnings Yield | 3.3% | 2.4% | 1.9% | 1.3% | 1.1% | 4.3% | 0.36% | 0.31% | -2.1% | -4.2% | -1.9% | -3.6% |
आय विवरण 15
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $959M | $814M | $806M | $795M | $688M | $573M | $628M | $622M | $590M | $515M | $515M | $499M | $453M | $420M | $412M | $388M | |
| Cost of Revenue | · | $14M | $18M | $14M | $11M | $9M | $9M | $8M | $9M | $8M | $8M | $11M | $12M | $8M | $8M | $6M | |
| SG&A Expense | $440M | $318M | $302M | $292M | $286M | $276M | $288M | $234M | $242M | $243M | $219M | $204M | $222M | $243M | $183M | $186M | |
| Operating Expenses | $808M | $621M | $595M | $556M | $542M | $549M | $486M | $438M | $445M | $416M | $365M | $358M | $379M | $535M | $309M | $300M | |
| Operating Income | $152M | $193M | $211M | $239M | $146M | $24M | $142M | $184M | $145M | $99M | $150M | $141M | $74M | $-114M | $103M | $88M | |
| Interest Expense | · | · | · | · | · | · | · | · | · | $1M | · | $1M | $1M | $1M | · | $1M | |
| Other Non-op | $11M | $53M | $28M | $53M | $14M | $-9M | $21M | $6M | $-47M | $-65M | $48M | $-26M | $48M | $11M | $14M | $10M | |
| Pretax Income | $162M | $247M | $239M | $292M | $160M | $15M | $163M | $190M | $99M | $34M | $198M | $116M | $122M | $-103M | $118M | $98M | |
| Income Tax | $18M | $49M | $86M | $82M | $52M | $7M | $60M | $60M | $34M | $-9M | $50M | $32M | $26M | $-27M | $29M | $29M | |
| Net Income | $144M | $198M | $154M | $210M | $108M | $8M | $103M | $130M | $65M | $43M | $148M | $83M | $96M | $-77M | $89M | $68M | |
| EPS (Basic) | $1.43 | $1.97 | $1.53 | $2.11 | $1.09 | $0.08 | $1.05 | $1.28 | $0.64 | $0.43 | $1.52 | $0.85 | $0.98 | $-0.79 | $0.92 | $0.72 | |
| EPS (Diluted) | $1.39 | $1.91 | $1.49 | $2.04 | $1.06 | $0.08 | $1.00 | $1.24 | $0.63 | $0.42 | $1.49 | $0.82 | $0.95 | $-0.79 | $0.91 | $0.69 | |
| Shares (Basic) | 101,000,000 | 100,500,000 | -198,600,000 | 99,400,000 | 99,000,000 | 99,700,000 | -201,300,000 | 101,100,000 | 100,800,000 | 99,800,000 | -194,900,000 | 97,900,000 | 97,600,000 | 97,100,000 | -190,900,000 | 95,800,000 | |
| Shares (Diluted) | 104,200,000 | 103,400,000 | -203,500,000 | 102,500,000 | 101,000,000 | 102,500,000 | -208,100,000 | 104,300,000 | 103,900,000 | 103,600,000 | -197,400,000 | 101,100,000 | 100,200,000 | 97,100,000 | -193,300,000 | 99,000,000 | |
| EBITDA | $152M | $193M | · | $239M | $146M | $24M | · | $184M | $145M | $99M | · | $141M | $74M | $-114M | · | $88M |
बैलेंस शीट 25
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $332M | $266M | $713M | $340M | $264M | $194M | $233M | $349M | $140M | $396M | · | $294M | $160M | $104M | · | $212M | |
| Receivables | $887M | $768M | $687M | $728M | $596M | $516M | $479M | $481M | $468M | $451M | · | $418M | $388M | $392M | · | $301M | |
| Inventory | $104M | $64M | $69M | $69M | $57M | $59M | $57M | $46M | $42M | $37M | · | $29M | $32M | $33M | · | $37M | |
| Prepaid Expense | $217M | $225M | $171M | $178M | · | · | $48M | · | · | · | · | · | · | · | · | · | |
| Other Current Assets | $39M | $62M | $116M | $68M | $121M | $119M | $64M | $122M | $120M | $100M | · | $108M | $101M | $113M | · | $68M | |
| Current Assets | $1.64B | $2.44B | $2.52B | $2.16B | $1.75B | $1.64B | $1.72B | $1.88B | $1.67B | $1.80B | · | $1.65B | $1.50B | $1.43B | · | $1.21B | |
| PP&E (Net) | $90M | $91M | $90M | $97M | $92M | $87M | $83M | $80M | $80M | $75M | · | $69M | $66M | $63M | · | $61M | |
| PP&E (Gross) | · | · | $208M | · | · | · | $189M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $118M | · | · | · | $106M | · | · | · | · | · | · | · | · | · | |
| Goodwill | $501M | · | · | · | · | · | · | $6M | $6M | $6M | · | $6M | $6M | $6M | $5M | · | |
| Intangibles | $2.23B | · | · | $36M | $37M | $36M | · | $34M | $34M | $34M | · | $35M | $37M | $37M | · | · | |
| Other Non-current Assets | $59M | $74M | $60M | $20M | $22M | $15M | $52M | $62M | $58M | $51M | · | $43M | $36M | $25M | · | $10M | |
| Total Assets | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Accounts Payable | $808M | $773M | $674M | $584M | $490M | $475M | $462M | $393M | $358M | $417M | · | $503M | $392M | $356M | · | $298M | |
| Current Liabilities | $874M | $832M | $743M | $638M | $546M | $523M | $508M | $430M | $398M | $713M | · | $692M | $582M | $374M | · | $485M | |
| Capital Leases | $402M | $406M | $415M | $428M | $439M | $448M | $455M | $251M | $256M | $253M | · | $86M | $89M | $90M | · | $97M | |
| Deferred Tax | $92M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-current Liabilities | $298M | $261M | $220M | $196M | $210M | $182M | $166M | $135M | $141M | $120M | · | $69M | $88M | $41M | · | $17M | |
| Total Liabilities | $1.67B | $1.50B | $1.38B | $1.26B | $1.20B | $1.15B | $1.13B | $816M | $796M | $1.09B | · | $846M | $760M | $675M | · | $599M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Retained Earnings | $724M | $590M | $448M | $294M | $84M | $-5M | $29M | $81M | $-49M | $-114M | · | $-305M | $-388M | $-483M | · | $-496M | |
| AOCI | $5M | $400.0K | $13M | $13M | $12M | $9M | $6M | $14M | $2M | $3M | · | $-2M | $-1M | $-3M | · | $-14M | |
| Stockholders' Equity | $3.69B | $3.41B | $3.25B | $3.00B | $2.69B | $2.54B | $2.59B | $2.72B | $2.51B | $2.39B | $2.23B | $2.00B | $1.85B | $1.68B | $1.71B | $1.54B | |
| Liabilities + Equity | $5.36B | $4.91B | $4.63B | $4.27B | $3.89B | $3.69B | $3.72B | $3.54B | $3.31B | $3.47B | · | $2.85B | $2.61B | $2.36B | · | $2.14B | |
| Shares Outstanding | 101,600,000 | 100,600,000 | 100,100,000 | 99,700,000 | 99,000,000 | 99,000,000 | 99,400,000 | 101,200,000 | 100,900,000 | 100,600,000 | · | 98,200,000 | 97,600,000 | 97,500,000 | · | 96,100,000 |
नकदी प्रवाह 12
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock-based Comp | $65M | $57M | $59M | $54M | $53M | $53M | $66M | $42M | $43M | $44M | $38M | $48M | $68M | $40M | $44M | $43M | |
| Amort. of Intangibles | $16M | $100.0K | $1M | $1M | $1M | $1M | $900.0K | $900.0K | $900.0K | $900.0K | $800.0K | $900.0K | $900.0K | $900.0K | $500.0K | $0 | |
| Operating Cash Flow | $136M | $146M | $388M | $228M | $102M | $65M | $242M | $158M | $65M | $130M | $124M | $212M | $180M | $-125M | $143M | $99M | |
| CapEx | $8M | $9M | $-2M | $13M | $12M | $11M | $7M | $8M | $12M | $11M | $5M | $8M | $7M | $8M | $2M | $-2M | |
| Investing Cash Flow | $-135M | $-506M | $-53M | $-197M | $-29M | $14M | $-68M | $25M | $-28M | $-55M | $-202M | $-97M | $-126M | $-42M | $-116M | $-61M | |
| Stock Issued | $85M | $24M | $37M | $46M | $14M | $32M | $10M | $26M | $16M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Stock Repurchased | $12M | $54M | $0 | $0 | $18M | $150M | $300M | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Stock Activity | · | $-30M | · | · | · | $-118M | · | · | · | $70M | · | · | · | $8M | · | · | |
| Financing Cash Flow | $63M | $-86M | $37M | $46M | $-3M | $-118M | $-290M | $26M | $-293M | $70M | $35M | $19M | $3M | $8M | $25M | $11M | |
| Net Change in Cash | $64M | $-446M | $373M | $76M | $70M | $-39M | $-116M | $209M | $-257M | $145M | $-43M | $134M | $57M | $-159M | $51M | $49M | |
| Free Cash Flow | · | $137M | · | · | · | $54M | · | · | · | $119M | · | · | · | $-134M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $118M | · | · | · | $-135M | · | · |
लाभप्रदता 7
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| Net Margin | 15.1% | 24.3% | · | 26.4% | 15.6% | 1.4% | · | 20.9% | 11.0% | 8.4% | · | 16.7% | 21.1% | -18.2% | · | 17.7% | |
| Pretax Margin | 16.9% | 30.3% | · | 36.7% | 23.2% | 2.6% | · | 30.6% | 16.7% | 6.7% | · | 23.2% | 26.9% | -24.6% | · | 25.2% | |
| EBITDA Margin | 15.8% | 23.7% | · | 30.1% | 21.2% | 4.1% | · | 29.5% | 24.6% | 19.3% | · | 28.3% | 16.3% | -27.2% | · | 22.6% | |
| ROA | 3.1% | 4.6% | · | 5.4% | 3.0% | 0.22% | · | 4.1% | 2.2% | 1.5% | · | 3.3% | 4.1% | -3.4% | · | 3.3% | |
| ROE | 4.5% | 6.7% | · | 7.3% | 4.1% | 0.32% | · | 5.5% | 3.0% | 2.1% | · | 4.7% | 5.8% | -5.0% | · | 4.7% | |
| ROIC | 3.6% | 4.5% | · | 5.7% | 3.6% | 0.50% | · | 4.6% | 3.8% | 5.2% | · | 5.1% | 3.1% | -5.0% | · | 4.0% |
तरलता और शोधन क्षमता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 2.9 | · | 3.4 | 3.2 | 3.1 | · | 4.4 | 4.2 | 2.5 | · | 2.4 | 2.6 | 3.8 | · | 2.5 | |
| Quick Ratio | 1.4 | 1.2 | · | 1.7 | 1.6 | 1.4 | · | 1.9 | 1.5 | 1.2 | · | 1.0 | 0.9 | 1.3 | · | 1.1 | |
| Interest Coverage | · | · | · | · | · | · | · | · | · | 90.3 | · | 128.4 | 56.6 | -103.8 | · | 73.2 |
दक्षता 3
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | |
| Inventory Turnover | · | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.2 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | |
| Receivables Turnover | 1.3 | 1.3 | · | 1.3 | 1.3 | 1.2 | · | 1.4 | 1.4 | 1.2 | · | 1.4 | 1.4 | 1.3 | · | 1.7 |
मूल्यांकन (TTM) 10
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $3.26B | $2.87B | · | $2.68B | $2.47B | $2.30B | · | $2.23B | $2.06B | $1.89B | · | $1.76B | $1.64B | $1.50B | · | $1.37B | |
| Net Income TTM | $659M | $523M | · | $455M | $310M | $246M | · | $321M | $287M | $145M | · | $170M | $70M | $-11M | · | $88M | |
| Market Cap | $17.12B | $13.25B | · | $14.00B | $12.44B | $10.95B | · | $11.66B | $13.89B | $13.87B | · | $11.05B | $9.20B | $9.87B | · | $10.21B | |
| P/E | 26.3 | 25.9 | · | 31.8 | 41.8 | 46.7 | · | 37.0 | 48.8 | 98.5 | · | 67.4 | 140.7 | -723.0 | · | 120.7 | |
| P/S | 5.3 | 4.6 | · | 5.2 | 5.0 | 4.8 | · | 5.2 | 6.8 | 7.4 | · | 6.3 | 5.6 | 6.6 | · | 7.4 | |
| P/B | 4.6 | 3.9 | · | 4.7 | 4.6 | 4.3 | · | 4.3 | 5.5 | 5.8 | · | 5.5 | 5.0 | 5.9 | · | 6.6 | |
| P / Tangible Book | 17.7 | 3.9 | · | 4.7 | 4.7 | 4.4 | · | 4.4 | 5.6 | 5.9 | · | 5.6 | 5.1 | 6.0 | · | 6.6 | |
| P / Cash Flow | · | 90.9 | · | · | · | 169.0 | · | · | · | 106.5 | · | · | · | -78.8 | · | · | |
| P / FCF | · | 96.9 | · | · | · | 202.4 | · | · | · | 116.5 | · | · | · | -73.8 | · | · | |
| Earnings Yield | 3.8% | 3.9% | · | 3.1% | 2.4% | 2.1% | · | 2.7% | 2.1% | 1.0% | · | 1.5% | 0.71% | -0.14% | · | 0.83% |
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
आय विवरण
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| राजस्व | $2.86B | $2.36B | $1.89B | $1.49B | $1.13B |
| परिचालन मार्जिन % | 21.6% | 24.2% | 13.3% | 16.7% | 9.0% |
| शुद्ध आय | $479M | $341M | $250M | $154M | $90M |
| तनुकरणित EPS | $4.67 | $3.29 | $2.47 | $1.56 | $0.92 |
बैलेंस शीट
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| वर्तमान अनुपात | 3.4 | 3.4 | 2.5 | 2.7 | 4.0 |
| त्वरित अनुपात | 1.9 | 1.4 | 1.1 | 1.1 | 3.6 |
नकदी प्रवाह
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $749M | $557M | $362M | $323M | $233M |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
ट्रेडिंग सिग्नल प्रवेश मूल्य और जोखिम/इनाम अनुपात के साथ हालिया खरीद/बिक्री संकेत
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर पूर्ण फंडामेंटल में किसी भी पंक्ति के बगल में ➕ पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
संस्थागत मालिक (13F) 827 फाइलर्स · $10.1B कुल · तिथि अनुसार 30 जून 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 153 (+61 पिछली तिमाही की तुलना में) | 62 (-37 पिछली तिमाही की तुलना में) | 300 (+11 पिछली तिमाही की तुलना में) | 223 (+8 पिछली तिमाही की तुलना में) | +9.4M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| Dodge & Cox | $941218594 | 5584707 | 9.32% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $838307078 | 4974083 | 8.30% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $766048708 | 4545339 | 7.59% | शेयर |
| STATE STREET CORP | $739126759 | 4385598 | 7.32% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $393680402 | 2335897 | 3.90% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $349922479 | 2076260 | 3.47% | शेयर |
| Vestal Point Capital, LP | $316845800 | 1880000 | 3.14% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $294151210 | 1750392 | 2.91% | शेयर |
| RTW INVESTMENTS, LP | $213689740 | 1267925 | 2.12% | शेयर |
| NORGES BANK | $164132866 | 973880 | 1.63% | शेयर |
| FIRST TRUST ADVISORS LP | $155578851 | 923125 | 1.54% | शेयर |
| JACOBS LEVY EQUITY MANAGEMENT, INC | $122375286 | 726112 | 1.21% | शेयर |
| TWO SIGMA ADVISERS, LP | $119504823 | 842592 | 1.18% | शेयर |
| Swedbank AB | $109730107 | 651082 | 1.09% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $109170737 | 647763 | 1.08% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $109070816 | 647171 | 1.08% | शेयर |
| VICTORY CAPITAL MANAGEMENT INC | $104238729 | 618499 | 1.03% | शेयर |
| Caisse de depot et placement du Quebec | $91002327 | 539961 | 0.90% | शेयर |
| ARMISTICE CAPITAL, LLC | $90307457 | 535838 | 0.89% | शेयर |
| PRIMECAP MANAGEMENT CO/CA/ | $82807988 | 491340 | 0.82% | शेयर |
| AMERIPRISE FINANCIAL INC | $79666260 | 472708 | 0.79% | शेयर |
| Hood River Capital Management LLC | $79082184 | 469233 | 0.78% | शेयर |
| ROYAL BANK OF CANADA | $73348000 | 435207 | 0.73% | शेयर |
| Pictet Asset Management Holding SA | $72751030 | 430635 | 0.72% | शेयर |
| Gotham Asset Management, LLC | $62622213 | 371568 | 0.62% | शेयर |
| Fiera Capital Corp | $61558083 | 365254 | 0.61% | शेयर |
| BlackRock, Inc. | $61129161 | 362709 | 0.61% | शेयर |
| ALLIANCEBERNSTEIN L.P. | $60767710 | 461270 | 0.60% | शेयर |
| Vinva Investment Management Ltd | $58838530 | 346109 | 0.58% | शेयर |
| AustralianSuper Pty Ltd | $58817535 | 348993 | 0.58% | शेयर |
| GOLDMAN SACHS GROUP INC | $58206259 | 345366 | 0.58% | शेयर |
| BRAIDWELL LP | $56656579 | 336171 | 0.56% | शेयर |
| RHUMBLINE ADVISERS | $52723054 | 312832 | 0.52% | शेयर |
| Clearbridge Investments, LLC | $47391031 | 281194 | 0.47% | शेयर |
| SEIZERT CAPITAL PARTNERS, LLC | $46740991 | 277337 | 0.46% | शेयर |
| Swiss National Bank | $45319062 | 268900 | 0.45% | शेयर |
| BARCLAYS PLC | $44228304 | 262428 | 0.44% | शेयर |
| ENVESTNET ASSET MANAGEMENT INC | $44187600 | 262192 | 0.44% | शेयर |
| WORLDQUANT MILLENNIUM ADVISORS LLC | $44038027 | 261299 | 0.44% | शेयर |
| Candriam S.C.A. | $43932854 | 260926 | 0.44% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $43921064 | 260605 | 0.43% | शेयर |
| FMR LLC | $40551501 | 240612 | 0.40% | शेयर |
| PRINCIPAL FINANCIAL GROUP INC | $40285595 | 239034 | 0.40% | शेयर |
| California Public Employees Retirement System | $39090345 | 231942 | 0.39% | शेयर |
| RENAISSANCE GROUP LLC | $38589515 | 228970 | 0.38% | शेयर |
| Assenagon Asset Management S.A. | $37516902 | 222606 | 0.37% | शेयर |
| NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | $37508000 | 222554 | 0.37% | शेयर |
| Sumitomo Mitsui Trust Group, Inc. | $36317270 | 215488 | 0.36% | शेयर |
| Carmignac Gestion | $36083344 | 214100 | 0.36% | शेयर |
| PFM Health Sciences, LP | $35966549 | 213407 | 0.36% | शेयर |
| Bridgewater Associates, LP | $34663773 | 205677 | 0.34% | शेयर |
| LOS ANGELES CAPITAL MANAGEMENT LLC | $34304966 | 203548 | 0.34% | शेयर |
| Nantahala Capital Management, LLC | $33707000 | 200000 | 0.33% | कॉल ऑप्शन |
| BANK OF AMERICA CORP /DE/ | $32143164 | 190721 | 0.32% | शेयर |
| MORGAN STANLEY | $32058612 | 190219 | 0.32% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $31213608 | 185200 | 0.31% | पुट ऑप्शन |
| FULLER & THALER ASSET MANAGEMENT, INC. | $30192001 | 179149 | 0.30% | शेयर |
| PRUDENTIAL FINANCIAL INC | $29909064 | 177465 | 0.30% | शेयर |
| SEB Asset Management AB | $29789208 | 176754 | 0.30% | शेयर |
| Ensign Peak Advisors, Inc | $29653059 | 175946 | 0.29% | शेयर |
| IEQ CAPITAL, LLC | $29628432 | 175800 | 0.29% | शेयर |
| MACKENZIE FINANCIAL CORP | $29609071 | 175685 | 0.29% | शेयर |
| NEW YORK STATE COMMON RETIREMENT FUND | $29573511 | 175474 | 0.29% | शेयर |
| Korea Investment CORP | $29154701 | 172989 | 0.29% | शेयर |
| PKO BP BANKOWY Universal Pension Society JSC | $28786115 | 170802 | 0.29% | शेयर |
| Zurich Insurance Group Ltd/FI | $28618254 | 169806 | 0.28% | शेयर |
| Impax Asset Management Group plc | $26965600 | 160000 | 0.27% | शेयर |
| Nearwater Capital Markets, Ltd | $26122925 | 155000 | 0.26% | शेयर |
| Mariner, LLC | $25627342 | 152055 | 0.25% | शेयर |
| Integral Health Asset Management, LLC | $25281000 | 150000 | 0.25% | शेयर |
| Rock Springs Capital Management LP | $24395441 | 144750 | 0.24% | शेयर |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $23738829 | 140854 | 0.24% | शेयर |
| Fisher Asset Management, LLC | $22769751 | 135104 | 0.23% | शेयर |
| Aware Super Pty Ltd as trustee of Aware Super | $22056175 | 130870 | 0.22% | शेयर |
| RAYMOND JAMES FINANCIAL INC | $22009323 | 130592 | 0.22% | शेयर |
| Hudson Bay Capital Management LP | $21909550 | 130000 | 0.22% | शेयर |
| Life Cycle Investment Partners Ltd | $21287319 | 126308 | 0.21% | शेयर |
| VIRGINIA RETIREMENT SYSTEMS ET Al | $20937370 | 147623 | 0.21% | शेयर |
| DNB Asset Management AS | $20280996 | 120337 | 0.20% | शेयर |
| JANE STREET GROUP, LLC | $20072518 | 119100 | 0.20% | पुट ऑप्शन |
| Sarissa Capital Management LP | $19639889 | 116533 | 0.19% | शेयर |
| Andra AP-fonden | $19522682 | 148191 | 0.19% | शेयर |
| AMERICAN CENTURY COMPANIES INC | $19061140 | 113099 | 0.19% | शेयर |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | $18885863 | 112059 | 0.19% | शेयर |
| Man Group plc | $18859404 | 111902 | 0.19% | शेयर |
| Mitsubishi UFJ Asset Management Co., Ltd. | $18788956 | 111484 | 0.19% | शेयर |
| UBS Group AG | $18243577 | 108248 | 0.18% | शेयर |
| Robeco Institutional Asset Management B.V. | $18197736 | 107976 | 0.18% | शेयर |
| LOOMIS SAYLES & CO L P | $18108412 | 107446 | 0.18% | शेयर |
| Retirement Systems of Alabama | $17527134 | 103997 | 0.17% | शेयर |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $17474389 | 132643 | 0.17% | शेयर |
| ING GROEP NV | $17224277 | 102200 | 0.17% | शेयर |
| Legal & General Group Plc | $17176748 | 101918 | 0.17% | शेयर |
| RICE HALL JAMES & ASSOCIATES, LLC | $16886364 | 100195 | 0.17% | शेयर |
| Universal- Beteiligungs- und Servicegesellschaft mbH | $16827572 | 99912 | 0.17% | शेयर |
| CWM, LLC | $16696728 | 126740 | 0.17% | शेयर |
| CAPITAL FUND MANAGEMENT S.A. | $16536148 | 98117 | 0.16% | शेयर |
| Clark Capital Management Group, Inc. | $15629612 | 92738 | 0.15% | शेयर |
| Distillate Capital Partners LLC | $15604993 | 92592 | 0.15% | शेयर |
| LAZARD ASSET MANAGEMENT LLC | $15399211 | 91371 | 0.15% | शेयर |
कंपनी के अंदरूनी सूत्र 42 इनसाइडर्स · 21 अधिकारी · 15 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Kyle Gano | Chief Executive Officer | 13 फ़रवरी 2025 M | 139907 | 0 | 0 | $0 |
| Matt Abernethy | Chief Financial Officer | 13 फ़रवरी 2025 M | 35810 | 0 | 0 | $0 |
| Timothy Coughlin | Chief Financial Officer | 6 फ़रवरी 2017 S | 137961 | 0 | 0 | $0 |
| David-Alexandre C Gros | President & COO | 6 फ़रवरी 2017 A | — | 0 | 0 | $0 |
| Ingrid Delaet | Chief Regulatory Officer | 10 जुलाई 2026 M | 16225 | 0 | 5 | $-3747962 |
| Darin Lippoldt | Chief Legal Officer | 9 जुलाई 2026 M | 54729 | 0 | 4 | $-3497443 |
| Sanjay Chandru Keswani | Chief Medical Officer | 2 जून 2026 F | 1479 | 0 | 0 | $0 |
| Julie Cooke | Chief Human Resources Officer | 2 जून 2026 M | 22374 | 0 | 1 | $-2200685 |
| David W. Boyer | Chief Corp. Affairs Officer | 13 फ़रवरी 2025 M | 3565 | 0 | 0 | $0 |
| Eiry Roberts | Chief Medical Officer | 13 फ़रवरी 2025 M | 35640 | 0 | 0 | $0 |
| Eric Benevich | Chief Commercial Officer | 13 फ़रवरी 2025 M | 44689 | 0 | 0 | $0 |
| Malcolm Lloyd-Smith | Chief Integration Officer | 8 फ़रवरी 2023 S | 42337 | 0 | 0 | $0 |
| Dimitri E. Grigoriadis | Chief Research Officer | 31 जनवरी 2022 A | 82273 | 0 | 0 | $0 |
| Haig P. Bozigian | Chief Development Officer | 8 फ़रवरी 2021 A | 157651 | 0 | 0 | $0 |
| Christopher Flint Obrien | Former Chief Medical Officer | 5 फ़रवरी 2018 A | 55946 | 0 | 0 | $0 |
| VALEUR JENSEN MARGARET E | EVP and General Counsel | 31 अगस्त 2011 A | 118256 | 0 | 0 | $0 |
| Richard J Ranieri | Sr. VP, Human Resources | 27 फ़रवरी 2008 A | 9667 | 0 | 0 | $0 |
| Wendall Wierenga | EVP, Research & Development | 19 जनवरी 2006 A | 5023 | 0 | 0 | $0 |
| Henry Pan | Executive VP and CMO | 3 जून 2005 A | 11216 | 0 | 0 | $0 |
| Robert J Little | SVP, Commercial Operations | 18 फ़रवरी 2005 A | — | 0 | 0 | $0 |
| SAUNDERS JOHN | Vice President Research (Chem) | 18 दिसमबर 2003 S | 7966 | 0 | 0 | $0 |
| Leslie V Norwalk | निदेशक | 29 जुलाई 2026 M | 2430 | 0 | 2 | $-437584 |
| SHERWIN STEPHEN A | निदेशक | 5 जून 2026 M | 15860 | 0 | 5 | $-4132990 |
| William H Rastetter | निदेशक | 27 मई 2026 A | 43678 | 0 | 1 | $-2732760 |
| Kevin Charles Gorman | निदेशक | 27 मई 2026 A | 511293 | 0 | 1 | $-37824431 |
| Christine A Poon | निदेशक | 27 मई 2026 A | 4753 | 0 | 0 | $0 |
| POPS RICHARD F | निदेशक | 27 मई 2026 A | 37798 | 0 | 1 | $-2364750 |
| LYONS GARY A | निदेशक | 27 मई 2026 A | 122141 | 0 | 1 | $-2289150 |
| MORROW GEORGE J | निदेशक | 27 मई 2026 A | 10386 | 0 | 1 | $-2150550 |
| Johanna Mercier | निदेशक | 22 मई 2025 M | 3535 | 0 | 0 | $0 |
| Alfred Sandrock | निदेशक | 22 मई 2019 A | — | 0 | 0 | $0 |
| Corinne H Nevinny | निदेशक | 24 मई 2018 A | 43283 | 0 | 0 | $0 |
| Thomas W Mitchell | निदेशक | 28 मई 2015 A | 1000 | 0 | 0 | $0 |
| VALE WYLIE W | निदेशक | 25 मई 2011 A | 231372 | 0 | 0 | $0 |
| Adrian Adams | निदेशक | 30 जून 2006 A | — | 0 | 0 | $0 |
| NEUROCRINE BIOSCIENCES INC | 10% मालिक | 23 फ़रवरी 2023 P | 8575316 | 0 | 0 | $0 |
| Jude Onyia | — | 4 अगस्त 2026 G | 20996 | 0 | 1 | $-1762710 |
| Shalini Sharp | — | 27 मई 2026 A | 4088 | 0 | 0 | $0 |
| MOLLICA JOSEPH A | — | 22 मई 2017 A | 56042 | 0 | 0 | $0 |
| HAWRAN PAUL W | — | 18 सितमबर 2006 J | 132000 | 0 | 0 | $0 |
| Lawrence Steinman | — | 2 मार्च 2005 S | 15500 | 0 | 0 | $0 |
| CONLON PAUL J | — | 16 दिसमबर 2003 S | 57335 | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
कार्यकर्ता और 5%+ मालिक 1 होल्डिंग
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Neurocrine Biosciences, Inc. ×3 फाइलिंग | 24 फ़रवरी 2023 | — | प्रारंभिक फाइलिंग | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ईटीएफ स्वामित्व 129 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| IBRN · iShares Trust | 3.71% | 1793 SH | 8 अगस्त 2026 | दैनिक |
| PBE · Invesco Exchange-Traded Fund Trust | 2.51% | 55704 SH | 8 अगस्त 2026 | दैनिक |
| MCOW · Pacer Funds Trust | 2.17% | 162 NS | 30 अप्रैल 2026 | N-PORT |
| FGSI · First Trust Exchange-Traded Fund IV | 2.01% | 457 NS | 30 अप्रैल 2026 | N-PORT |
| POWA · Invesco Exchange-Traded Self-Indexe… | 1.97% | 22094 SH | 8 अगस्त 2026 | दैनिक |
| SMRI · EA Series Trust | 1.95% | 79947 NS | 30 अप्रैल 2026 | N-PORT |
| GRPM · Invesco Exchange-Traded Fund Trust | 1.78% | 55458 SH | 8 अगस्त 2026 | दैनिक |
| XMHQ · Invesco Exchange-Traded Fund Trust | 1.74% | 599955 SH | 8 अगस्त 2026 | दैनिक |
| BUL · Pacer Funds Trust | 1.66% | 16032 NS | 30 अप्रैल 2026 | N-PORT |
| BBP · ETFis Series Trust I | 1.38% | 6192 NS | 30 अप्रैल 2026 | N-PORT |
| ILDR · First Trust Exchange-Traded Fund VI… | 1.29% | 23318 NS | 31 मई 2026 | N-PORT |
| IBB · iShares Trust | 1.22% | 725434 SH | 8 अगस्त 2026 | दैनिक |
| RFG · Invesco Exchange-Traded Fund Trust | 1.16% | 25502 SH | 8 अगस्त 2026 | दैनिक |
| AGNG · Global X Funds | 1.12% | 5792 NS | 31 मई 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 1.12% | 5472 SH | 8 अगस्त 2026 | दैनिक |
| LABU · Direxion Shares ETF Trust | 0.95% | 37476 NS | 30 अप्रैल 2026 | N-PORT |
| AGRW · ALLSPRING EXCHANGE-TRADED FUNDS TRU… | 0.93% | 7516 NS | 30 अप्रैल 2026 | N-PORT |
| IVOG · VANGUARD ADMIRAL FUNDS | 0.89% | 99214 SH | 8 अगस्त 2026 | दैनिक |
| FXH · First Trust Exchange-Traded AlphaDE… | 0.87% | 57454 NS | 30 अप्रैल 2026 | N-PORT |
| IJK · iShares Trust | 0.86% | 588275 SH | 8 अगस्त 2026 | दैनिक |
| COWG · Pacer Funds Trust | 0.81% | 132963 NS | 30 अप्रैल 2026 | N-PORT |
| BIB · ProShares Trust | 0.80% | 3712 NS | 31 मई 2026 | N-PORT |
| QQQJ · Invesco Exchange-Traded Fund Trust … | 0.79% | 57321 SH | 8 अगस्त 2026 | दैनिक |
| TMFX · RBB Fund, Inc. | 0.76% | 1542 NS | 31 मई 2026 | N-PORT |
| ABOT · Abacus FCF ETF Trust | 0.72% | 240 NS | 30 अप्रैल 2026 | N-PORT |
| CLSE · Trust for Professional Managers | 0.66% | 25529 NS | 31 मई 2026 | N-PORT |
| MIDE · DBX ETF Trust | 0.64% | 136 NS | 29 मई 2026 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund Tr… | 0.63% | 533 NS | 30 अप्रैल 2026 | N-PORT |
| IQSM · New York Life Investments ETF Trust | 0.55% | 13166 NS | 30 अप्रैल 2026 | N-PORT |
| SMDX · Tidal Trust III | 0.55% | 5215 NS | 30 अप्रैल 2026 | N-PORT |
| XJH · iShares Trust | 0.51% | 13589 SH | 8 अगस्त 2026 | दैनिक |
| ISCG · iShares Trust | 0.50% | 31557 SH | 8 अगस्त 2026 | दैनिक |
| QVMM · Invesco Exchange-Traded Fund Trust … | 0.49% | 13131 SH | 8 अगस्त 2026 | दैनिक |
| VBK · VANGUARD INDEX FUNDS | 0.46% | 1331820 SH | 8 अगस्त 2026 | दैनिक |
| IVOO · VANGUARD ADMIRAL FUNDS | 0.46% | 162408 SH | 8 अगस्त 2026 | दैनिक |
| QLV · FlexShares Trust | 0.46% | 5915 NS | 30 अप्रैल 2026 | N-PORT |
| IJH · iShares Trust | 0.44% | 3469295 SH | 8 अगस्त 2026 | दैनिक |
| SDG · iShares Trust | 0.42% | 4563 SH | 8 अगस्त 2026 | दैनिक |
| FNY · First Trust Exchange-Traded AlphaDE… | 0.40% | 15614 NS | 30 अप्रैल 2026 | N-PORT |
| IWP · iShares Trust | 0.39% | 493090 SH | 8 अगस्त 2026 | दैनिक |
| PTMC · Pacer Funds Trust | 0.39% | 11519 NS | 30 अप्रैल 2026 | N-PORT |
| USMV · iShares Trust | 0.35% | 534448 SH | 8 अगस्त 2026 | दैनिक |
| MVV · ProShares Trust | 0.34% | 3468 NS | 31 मई 2026 | N-PORT |
| SXQG · EXCHANGE TRADED CONCEPTS TRUST | 0.34% | 1461 NS | 31 मई 2026 | N-PORT |
| BKMC · BNY Mellon ETF Trust | 0.34% | 16076 NS | 30 अप्रैल 2026 | N-PORT |
| SCHM · SCHWAB STRATEGIC TRUST | 0.29% | 271303 NS | 31 मई 2026 | N-PORT |
| MIDU · Direxion Shares ETF Trust | 0.26% | 1662 NS | 30 अप्रैल 2026 | N-PORT |
| BBMC · J.P. Morgan Exchange-Traded Fund Tr… | 0.26% | 40014 NS | 30 अप्रैल 2026 | N-PORT |
| IYH · iShares Trust | 0.26% | 59243 SH | 8 अगस्त 2026 | दैनिक |
| ISCB · iShares Trust | 0.25% | 4488 SH | 8 अगस्त 2026 | दैनिक |